ArticleHeadache2022
Real-world assessment of the relationship between migraine-related disability and healthcare costs in the United States.
Article in Headache, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Prevalence of orofacial and head pain: an umbrella review of systematic reviews.Journal of oral & facial pain and headache · 2024Pooled it
- Altered static-dynamic interhemispheric connectivity and transcriptional features underlying lateralization in patients with migraine.The journal of headache and pain · 2026Article
- First myocardial infarction: risk factors, symptoms, and medical therapy.European heart journal · 2025Article
- Differences in pharmacological migraine treatment across different levels of clinical headache care - a cross-sectional study.The journal of headache and pain · 2025Observational
- Symptoms across the phases of the migraine cycle from the patient's perspective: Results of the MiCOAS qualitative study.Headache · 2025Article
- Understanding Data and Opportunities Focused on Value: A Single-Center Experience in Headache Care.Neurology. Clinical practice · 2025Article
- A Retrospective Analysis of Disease Epidemiology, Comorbidity Burden, Treatment Patterns, and Healthcare Resource Utilization of Migraine in the United Arab Emirates.Pain and therapy · 2024Article
- Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison.Journal of comparative effectiveness research · 2024Article
- Treatment patterns of patients with migraine eligible for anti-CGRP pathway monoclonal antibodies.Frontiers in neurology · 2024Article
- The Association between Serum Total Bilirubin and Severe Headaches or Migraine in American Adults.Current neurovascular research · 2024Article
- Feasibility and Usability of a Mobile App-Based Interactive Care Plan for Migraine in a Community Neurology Practice: Development and Pilot Implementation Study.JMIR formative research · 2023Article
- Real-world evidence of eteplirsen treatment effects in patients with Duchenne muscular dystrophy in the USA.Journal of comparative effectiveness research · 2023Article
- Migraine and heart: A reality check.Global cardiology science & practice · 2023Review
- Migraine symptoms, healthcare resources utilization and disease burden in a large Polish migraine cohort : Results from 'Migraine in Poland'-a nationwide cross-sectional survey.The journal of headache and pain · 2023Article
- [Consensus statement of the migraine and headache societies (DMKG, ÖKSG, and SKG) on the duration of pharmacological migraine prophylaxis].Der Nervenarzt · 2023Review
- Real-world assessment of the relationship between migraine-related disability and healthcare costs in the United States.Headache · 2022Article
- Migraine Symptoms Induced by an Auricular Piercing in a 27-Year-Old Female: A Case Report.Case reports in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of this study was to determine the associations among migraine disability assessment scores, healthcare resource utilization (HCRU; medical visits and pharmacy use) and direct medical costs among people with episodic migraine in a real-world setting.
backgroundMigraine is a public health concern associated with a substantial economic burden in the United States. However, the association between migraine disability and direct medical costs among people with migraine is unknown.
methodThis retrospective, cohort study used claims and electronic health record data from the Decision Resources Group database. Adults with migraine with or without aura, defined by International Classification of Disease Revision 9 (ICD-9) or ICD Revision 10 (ICD-10) codes, and a completed Migraine Disability Assessment Scale (MIDAS) questionnaire from January 2016 to December 2018 were included (chronic migraine codes not included). The associations of MIDAS score with the cost of HCRU for the 6 months after MIDAS assessment were explored. Results were stratified by treatment setting.
resultsAmong 7662 included patients, MIDAS scores were distributed as: 3348 (43.7%; I, little/none), 1107 (14.4%; II, mild), 1225 (16.0%; III, moderate), 893 (11.7%; IVa, severe), and 1089 (14.2%; IVb, very severe). Worsening disability was associated with higher medical costs (adjusted from a multivariable model). In the primary care setting, healthcare visit costs were $206 (95% confidence interval: $144-294) for grade I and $631 ($384-1036) for grade IVb patients; corresponding pharmacy costs were $203 (grade I; $136-301) and $719 (grade IVb; $410-1259). For specialty care (e.g., neurologist), healthcare visits cost $509 ($411-629) for grade I and $885 ($634-1236) for grade IVb patients; corresponding pharmacy costs were $494 (grade I; $378-645) and $1020 (grade IVb; $643-1620).
conclusionHigher levels of migraine-related disability (MIDAS assessed) are associated with increased HCRU costs among Americans with episodic migraine. Migraine disability assessment could be useful in the development, testing, and prescription of cost-effective treatments for people with high migraine-related disability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.